Functional Analysis of Adhesion GPCR Latrophilin 2 (ADGRL2) in MDA-MB-231 Human Breast Cancer Cells

  • 0Laboratory of Molecular Signal Transduction, Graduate School of Science and Technology, Nara Institute of Science and Technology, Nara, Japan.

Summary

This summary is machine-generated.

Latrophilin-2 (LPHN2) significantly impacts breast cancer progression by influencing cell migration and proliferation. Its signaling pathways offer potential therapeutic targets for intervention.

Area Of Science

  • Oncology
  • Cell Biology
  • Molecular Signaling

Background

  • The tumor microenvironment critically affects cancer progression, influencing cell growth, migration, and invasiveness.
  • Adhesion G protein-coupled receptors (aGPCRs) are key mediators of cell-cell and cell-extracellular matrix interactions.
  • Latrophilin-2 (LPHN2), an aGPCR, has an emerging but not fully understood role in cancer.

Purpose Of The Study

  • To investigate the functional roles of Latrophilin-2 (LPHN2) in breast cancer progression.
  • To elucidate the specific signaling pathways activated by LPHN2 in breast cancer cells.
  • To explore LPHN2 as a potential therapeutic target for breast cancer.

Main Methods

  • Utilized MDA-MB-231 breast cancer cells, including LPHN2-deficient and knockout variants.
  • Performed 3D culture for invasion assays, proliferation assays, and cell adhesion assays.
  • Employed reporter assays, pharmacological inhibition, and Western blotting to analyze signaling pathways.

Main Results

  • LPHN2 deficiency in MDA-MB-231 cells led to reduced invasion, proliferation, collagen I adhesion, and migration.
  • The C-terminal fragment (CTF) of LPHN2 activates SRE and CREB transcription via ROCK and PKA pathways.
  • LPHN2 signaling involves coupling to Gα12/13 and Gαs pathways, crucial for cell migration.

Conclusions

  • Latrophilin-2 plays a significant role in promoting breast cancer cell behaviors essential for progression.
  • LPHN2 signaling pathways, including Gα12/13 and Gαs, are critical for mediating its pro-cancer effects.
  • Targeting LPHN2 and its downstream signaling pathways presents a promising therapeutic strategy for breast cancer intervention.